Tests a drug-coated balloon for narrowed heart arteries
Tests the Prevail drug-coated balloon in adults with coronary artery disease.
Key facts
- Who runs it
- Medtronic Vascular
- Where
- Daegu and Seoul, South KoreaSee the 5 sitesAlso in 8 other countries, 74 sites
- Trial code
- Registry title
- Prevail Global Study
- Status
- Recruiting
- People taking part
- 1,205 people, planned
- Started
- 24 Feb 2025
- Expected to end
- Feb 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Prevail DCB
- Agent DCB
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease and angina, a positive functional test, or stable NSTEMI, to test the Prevail drug-coated balloon.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stable or unstable angina, a positive functional test, or stable NSTEMI. Life expectancy of more than 1 year.
- Earlier treatment
- No previous PCI of the target vessel within 6 months before the procedure.
Main reasons for not taking part
- Acute heart attack (MI)
- Kidney insufficiency or failure
- History of stroke or transient ischemic attack (TIA)
- Known allergy to paclitaxel, antiplatelet medicines, or contrast media that cannot be pre-medicated
- Left ventricular ejection fraction below 30%
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- ≥ 18 years
- Negative pregnancy test
- Stable or unstable angina, positive functional test, or stable NSTEMI
- Life expectancy >1 year
- Willing and able to cooperate with study procedures and required follow up evaluations
Who cannot take part
- Previous PCI of the target vessel within 6 months prior to the procedure
- Planned surgery that would cause interruption in recommended DAPT duration per current guidelines
- Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS or other coronary artery imaging procedures
- Known hypersensitivity or contraindication to antiplatelet medications or a sensitivity to contrast media which cannot be adequately pre-medicated
- History of an allergic reaction or significant sensitivity to paclitaxel or any other analogue or derivative
- Renal insufficiency (or failure)
- History of a stroke or transient ischemic attack (TIA)
- Active peptic ulcer or upper gastrointestinal (GI) bleeding
- History of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Platelet count < 100,000 cells/mm³ or > 700,000 cells/mm³, or a white blood cell (WBC) count < 3,000 cells/mm³
- Documented left ventricular ejection fraction (LVEF) <30%
- Acute MI
- Planned PCI of any vessel within 72 hours post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure
Where in South Korea
Also in 8 other countries, 74 sites
- Keimyung University Dongsan HospitalDaegu, South KoreaContact: Yoon Hyuck Jun (principal investigator)Taking people
- Asan Medical CenterSeoul, South KoreaContact: DukWoo Park (principal investigator)Taking people
- Korea University Anam HospitalSeoul, South KoreaContact: Soon Jun Hong (principal investigator)Taking people
- Seoul National University HospitalSeoul, South KoreaContact: Koo Bon Kwon (principal investigator)Taking people
- Seoul Saint Marys HospitalSeoul, South KoreaContact: Byung-Hee Hwang (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
The 2 groups in the trial
- ISR Cohort Prevail DCBTreatment being tested
To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.
Treatment: Prevail DCB and Agent DCB
- DNSV Cohort (RVD 2.0 - 2.75mm)Treatment being tested
To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.
Treatment: Prevail DCB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).
- Plain-language title
- Tests a drug-coated balloon for narrowed heart arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 21 October 2026